683 related articles for article (PubMed ID: 31208030)
1. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
3. Opportunities in immunotherapy of ovarian cancer.
Coukos G; Tanyi J; Kandalaft LE
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
Wang W; Zou W; Liu JR
Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
[No Abstract] [Full Text] [Related]
5. Adoptive immunotherapy against ovarian cancer.
Mittica G; Capellero S; Genta S; Cagnazzo C; Aglietta M; Sangiolo D; Valabrega G
J Ovarian Res; 2016 May; 9(1):30. PubMed ID: 27188274
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
Linette GP; Carreno BM
Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
[TBL] [Abstract][Full Text] [Related]
7. Tumor infiltrating lymphocytes in ovarian cancer.
Santoiemma PP; Powell DJ
Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
[TBL] [Abstract][Full Text] [Related]
9. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
10. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
Yamashita H; Nakayama K; Ishikawa M; Ishibashi T; Nakamura K; Sawada K; Yoshimura Y; Tatsumi N; Kurose S; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623180
[TBL] [Abstract][Full Text] [Related]
11. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Gide TN; Wilmott JS; Scolyer RA; Long GV
Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
[TBL] [Abstract][Full Text] [Related]
12. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
[TBL] [Abstract][Full Text] [Related]
13. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
14. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
15. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
Front Immunol; 2021; 12():808964. PubMed ID: 35095898
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
[TBL] [Abstract][Full Text] [Related]
18. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
[TBL] [Abstract][Full Text] [Related]
19. Current status of immunotherapy for gastrointestinal stromal tumor.
Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
[TBL] [Abstract][Full Text] [Related]
20. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
